Saad S. Kenderian T Cell Engineering Laboratory Mayo Clinic, Rochester Biography Publications Institution JoVE Articles Saad S. Kenderian has not added a biography. If you are Saad S. Kenderian and would like to personalize this page please email our Author Liaison for assistance. Publications CAR-T Cell Therapy: the Efficacy and Toxicity Balance Current Hematologic Malignancy Reports. Feb, 2023 | Pubmed ID: 36763238 GM-CSF Disruption in CART Cells Modulates T Cell Activation and Enhances CART Cell Anti-tumor Activity Leukemia. Jun, 2022 | Pubmed ID: 35440691 Challenges of CAR T-cell Therapy in CLL: Lessons Learned Experimental Hematology. Feb, 2022 | Pubmed ID: 35150777 Chronic Lymphocytic Leukemia (CLL) with Reed-Sternberg-like Cells Vs Classic Hodgkin Lymphoma Transformation of CLL: Does This Distinction Matter? Blood Cancer Journal. 01, 2022 | Pubmed ID: 35091549 Targeting Cancer-Associated Fibroblasts in the Bone Marrow Prevents Resistance to CART-Cell Therapy in Multiple Myeloma Blood. Jan, 2022 | Pubmed ID: 35090171 Humoral and Cellular Immune Responses to Recombinant Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia and Monoclonal B Cell Lymphocytosis American Journal of Hematology. 01, 2022 | Pubmed ID: 34699616 Differential Transcriptomic Profiling in Ibrutinib-naïve Versus Ibrutinib-resistant Richter Syndrome Hematological Oncology. Nov, 2021 | Pubmed ID: 34806797 Cause of Death in Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) Stratified by the CLL-International Prognostic Index Blood Cancer Journal. 08, 2021 | Pubmed ID: 34354039 Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity Cancer Immunology Research. 09, 2021 | Pubmed ID: 34244299 Distinct Immune Signatures in Chronic Lymphocytic Leukemia and Richter Syndrome Blood Cancer Journal. 05, 2021 | Pubmed ID: 33972504 The CLL International Prognostic Index Predicts Outcomes in Monoclonal B-cell Lymphocytosis and Rai 0 CLL Blood. 07, 2021 | Pubmed ID: 33876228 CART Cell Imaging: Paving the Way for Success in CART Cell Therapy Molecular Therapy Oncolytics. Mar, 2021 | Pubmed ID: 33816781 The Prognostic Significance of Del6q23 in Chronic Lymphocytic Leukemia American Journal of Hematology. 06, 2021 | Pubmed ID: 33749852 Resistance to CART Cell Therapy: Lessons Learned from the Treatment of Hematological Malignancies Leukemia & Lymphoma. 09, 2021 | Pubmed ID: 33682608 In Reply - Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019 Mayo Clinic Proceedings. 03, 2021 | Pubmed ID: 33673930 Venetoclax Treatment of Patients with Relapsed T-cell Prolymphocytic Leukemia Blood Cancer Journal. 03, 2021 | Pubmed ID: 33654067 CRISPR Takes the Front Seat in CART-Cell Development BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. Mar, 2021 | Pubmed ID: 33638865 Leukemic Extracellular Vesicles Induce Chimeric Antigen Receptor T cell Dysfunction in Chronic Lymphocytic Leukemia Molecular Therapy : the Journal of the American Society of Gene Therapy. 04, 2021 | Pubmed ID: 33388419 Atrial Fibrillation in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Risk Prediction, Management, and Clinical Outcomes Annals of Hematology. Jan, 2021 | Pubmed ID: 32488603 CART Cell Toxicities: New Insight into Mechanisms and Management Clinical Hematology International. Dec, 2020 | Pubmed ID: 33409484 GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study Mayo Clinic Proceedings. 11, 2020 | Pubmed ID: 33153629 The Role of 18F-FDG-PET in Detecting Richter's Transformation of Chronic Lymphocytic Leukemia in Patients Receiving Therapy with a B-cell Receptor Inhibitor Haematologica. 11, 2020 | Pubmed ID: 33131260 Anti-CD19 Chimeric Antigen Receptor T-cell Therapy in Acute Lymphocytic Leukaemia: a Systematic Review and Meta-analysis The Lancet. Haematology. Nov, 2020 | Pubmed ID: 33091355 A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy Neurologic Clinics. 11, 2020 | Pubmed ID: 33040871 Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies Frontiers in Immunology. 2020 | Pubmed ID: 32983132 Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia The Oncologist. 11, 2020 | Pubmed ID: 32886416 CRISPR Taking the Front Seat in Immunotherapy Journal of Cellular Immunology. 2020 | Pubmed ID: 32776020 Characteristics of Late Transplant-associated Thrombotic Microangiopathy in Patients Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation American Journal of Hematology. Jul, 2020 | Pubmed ID: 32618000 Incidence and Risk of Tumor Lysis Syndrome in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL) Treated with Venetoclax in Routine Clinical Practice Leukemia & Lymphoma. 10, 2020 | Pubmed ID: 32449401 Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy Nature Biotechnology. 08, 2020 | Pubmed ID: 32361713 CAR T-cell Therapy for the Management of Refractory/relapsed High-grade B-cell Lymphoma: a Practical Overview Bone Marrow Transplantation. 08, 2020 | Pubmed ID: 32305998 A Graduate-Level Interdisciplinary Curriculum in CAR-T Cell Therapy Mayo Clinic Proceedings. Innovations, Quality & Outcomes. Apr, 2020 | Pubmed ID: 32280931 The Impact of Dose Modification and Temporary Interruption of Ibrutinib on Outcomes of Chronic Lymphocytic Leukemia Patients in Routine Clinical Practice Cancer Medicine. 05, 2020 | Pubmed ID: 32187452 Baseline Immune Dysregulation in Autologous Stem Cell Transplant Recipients is Associated with a 'graft Versus Host'-like Syndrome and Poor Outcomes Bone Marrow Transplantation. 09, 2020 | Pubmed ID: 32161319 Addition of Venetoclax at Time of Progression in Ibrutinib-treated Patients with Chronic Lymphocytic Leukemia: Combination Therapy to Prevent Ibrutinib Flare American Journal of Hematology. 03, 2020 | Pubmed ID: 31788844 Myeloid Cell and Cytokine Interactions with Chimeric Antigen Receptor-T-cell Therapy: Implication for Future Therapies Current Opinion in Hematology. 01, 2020 | Pubmed ID: 31764168 Clinical Characteristics and Outcomes of Richter Transformation: Experience of 204 Patients from a Single Center Haematologica. Jun, 2019 | Pubmed ID: 31197071 Management of Cytokine Release Syndrome: an Update on Emerging Antigen-specific T Cell Engaging Immunotherapies Immunotherapy. Jul, 2019 | Pubmed ID: 31161844 Rapid Disease Progression Following Discontinuation of Ibrutinib in Patients with Chronic Lymphocytic Leukemia Treated in Routine Clinical Practice Leukemia & Lymphoma. Apr, 2019 | Pubmed ID: 31014142 CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies The AAPS Journal. Apr, 2019 | Pubmed ID: 30963322 IGH Translocations in Chronic Lymphocytic Leukemia: Clinicopathologic Features and Clinical Outcomes American Journal of Hematology. Mar, 2019 | Pubmed ID: 30575108 GM-CSF Inhibition Reduces Cytokine Release Syndrome and Neuroinflammation but Enhances CAR-T Cell Function in Xenografts Blood. Feb, 2019 | Pubmed ID: 30463995 Chimeric Antigen Receptor T-Cells: Successful Translation of the First Cell and Gene Therapy From Bench to Bedside Clinical and Translational Science. 11, 2018 | Pubmed ID: 30242965 Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib in Routine Clinical Practice at an Academic Medical Centre British Journal of Haematology. 11, 2018 | Pubmed ID: 30117139 Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia Cell. 05, 2018 | Pubmed ID: 29856956 Outcomes of a Large Cohort of Individuals with Clinically Ascertained High-count Monoclonal B-cell Lymphocytosis Haematologica. 06, 2018 | Pubmed ID: 29419435 Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. Dec, 2017 | Pubmed ID: 29143249 Liver Dysfunction in Chronic Lymphocytic Leukemia: Prevalence, Outcomes, and Pathological Findings American Journal of Hematology. Dec, 2017 | Pubmed ID: 28940587 Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia Methods in Molecular Biology (Clifton, N.J.). 2017 | Pubmed ID: 28735493 Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells Cancer Discovery. 10, 2017 | Pubmed ID: 28576927 Optimized Depletion of Chimeric Antigen Receptor T Cells in Murine Xenograft Models of Human Acute Myeloid Leukemia Blood. 04, 2017 | Pubmed ID: 28246194 Pharmacovigilance During Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL)/small Lymphocytic Lymphoma (SLL) in Routine Clinical Practice Leukemia & Lymphoma. 06, 2017 | Pubmed ID: 27820970 Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. Feb, 2017 | Pubmed ID: 27638367 The Microbiome and Immune Regulation After Transplantation Transplantation. Jan, 2017 | Pubmed ID: 27517729 Dual CD19 and CD123 Targeting Prevents Antigen-loss Relapses After CD19-directed Immunotherapies The Journal of Clinical Investigation. Aug, 2016 | Pubmed ID: 27571406 The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses Against Mantle Cell Lymphoma Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 06, 2016 | Pubmed ID: 26819453 Bone Marrow Findings of the Newly Described TEMPI Syndrome: when Erythrocytosis and Plasma Cell Dyscrasia Coexist Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc. Mar, 2015 | Pubmed ID: 25216227 Valutazione delle tossicità associate alle cellule T del recettore dell'antigene chimerico utilizzando un modello murino di xenotrapianto derivato dal paziente per la leucemia linfoblastica acuta Claudia Manriquez Roman1,2,3,4,5, R. Leo Sakemura1,2, Brooke L. Kimball1,2, Fang Jin6, Roman H. Khadka6, Mohamad M. Adada1,2, Elizabeth L. Siegler1,2, Aaron J. Johnson6, Saad S. Kenderian1,2,6 1T Cell Engineering Laboratory, Mayo Clinic, Rochester, 2Division of Hematology, Mayo Clinic, Rochester, 3Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, 4Department of Molecular Medicine, Mayo Clinic, Rochester, 5Regenerative Sciences PhD Program, Mayo Clinic, Rochester, 6Department of Immunology, Mayo Clinic, Rochester JoVE 64535 Cancer Research Imaging dinamico di cellule T del recettore dell'antigene chimerico con [18F] tomografia ad emissione di positroni tetrafluoroborato/tomografia computerizzata Reona Sakemura1,2, Michelle J. Cox1,2, Aditya Bansal3, Claudia Manriquez Roman1,2,4,5, Mehrdad Hefazi1,2, Cynthia J. Vernon3, Dianna L. Glynn3, Mukesh K. Pandey3, Timothy R. DeGrado3, Elizabeth L. Siegler1,2, Saad S. Kenderian1,2,5,6 1T Cell Engineering, Mayo Clinic, 2Division of Hematology, Mayo Clinic, 3Department of Radiology, Mayo Clinic, 4Regenerative Sciences PhD, Mayo Clinic, 5Department of Molecular Medicine, Mayo Clinic, 6Department of Immunology, Mayo Clinic JoVE 62334 Cancer Research Utilizzo di CRISPR/Cas9 per eliminare GM-CSF nelle celle CAR-T Rosalie M. Sterner1,2, Michelle J. Cox3, Reona Sakemura3, Saad S. Kenderian2,3 1Mayo Clinic Medical Scientist Training Program, Mayo Clinic College of Medicine and Science, 2Department of Immunology, Mayo Clinic, 3Division of Hematology, Mayo Clinic JoVE 59629 Cancer Research
Valutazione delle tossicità associate alle cellule T del recettore dell'antigene chimerico utilizzando un modello murino di xenotrapianto derivato dal paziente per la leucemia linfoblastica acuta Claudia Manriquez Roman1,2,3,4,5, R. Leo Sakemura1,2, Brooke L. Kimball1,2, Fang Jin6, Roman H. Khadka6, Mohamad M. Adada1,2, Elizabeth L. Siegler1,2, Aaron J. Johnson6, Saad S. Kenderian1,2,6 1T Cell Engineering Laboratory, Mayo Clinic, Rochester, 2Division of Hematology, Mayo Clinic, Rochester, 3Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, 4Department of Molecular Medicine, Mayo Clinic, Rochester, 5Regenerative Sciences PhD Program, Mayo Clinic, Rochester, 6Department of Immunology, Mayo Clinic, Rochester JoVE 64535 Cancer Research
Imaging dinamico di cellule T del recettore dell'antigene chimerico con [18F] tomografia ad emissione di positroni tetrafluoroborato/tomografia computerizzata Reona Sakemura1,2, Michelle J. Cox1,2, Aditya Bansal3, Claudia Manriquez Roman1,2,4,5, Mehrdad Hefazi1,2, Cynthia J. Vernon3, Dianna L. Glynn3, Mukesh K. Pandey3, Timothy R. DeGrado3, Elizabeth L. Siegler1,2, Saad S. Kenderian1,2,5,6 1T Cell Engineering, Mayo Clinic, 2Division of Hematology, Mayo Clinic, 3Department of Radiology, Mayo Clinic, 4Regenerative Sciences PhD, Mayo Clinic, 5Department of Molecular Medicine, Mayo Clinic, 6Department of Immunology, Mayo Clinic JoVE 62334 Cancer Research
Utilizzo di CRISPR/Cas9 per eliminare GM-CSF nelle celle CAR-T Rosalie M. Sterner1,2, Michelle J. Cox3, Reona Sakemura3, Saad S. Kenderian2,3 1Mayo Clinic Medical Scientist Training Program, Mayo Clinic College of Medicine and Science, 2Department of Immunology, Mayo Clinic, 3Division of Hematology, Mayo Clinic JoVE 59629 Cancer Research
